These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 30099860)

  • 1. Dynamics of circulating microRNAs as a novel indicator of clinical response to neoadjuvant chemotherapy in breast cancer.
    Zhu W; Liu M; Fan Y; Ma F; Xu N; Xu B
    Cancer Med; 2018 Sep; 7(9):4420-4433. PubMed ID: 30099860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating microRNAs as indicators in the prediction of neoadjuvant chemotherapy response in luminal B breast cancer.
    Zhang Z; Zhang H; Li C; Xiang Q; Xu L; Liu Q; Pang X; Zhang W; Zhang H; Zhang S; Duan X; Liu Y; Cui Y
    Thorac Cancer; 2021 Dec; 12(24):3396-3406. PubMed ID: 34751517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer.
    Liu B; Su F; Chen M; Li Y; Qi X; Xiao J; Li X; Liu X; Liang W; Zhang Y; Zhang J
    Hum Pathol; 2017 Jun; 64():44-52. PubMed ID: 28412211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating miR-34a and miR-125b as Promising non Invasive Biomarkers in Egyptian Locally Advanced Breast Cancer Patients.
    Kassem NM; Makar WS; Kassem HA; Talima S; Tarek M; Hesham H; El-Desouky MA
    Asian Pac J Cancer Prev; 2019 Sep; 20(9):2749-2755. PubMed ID: 31554373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNAs miR-7 and miR-340 predict response to neoadjuvant chemotherapy in breast cancer.
    Raychaudhuri M; Bronger H; Buchner T; Kiechle M; Weichert W; Avril S
    Breast Cancer Res Treat; 2017 Apr; 162(3):511-521. PubMed ID: 28181130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal A subtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel.
    Li Q; Liu M; Ma F; Luo Y; Cai R; Wang L; Xu N; Xu B
    PLoS One; 2014; 9(8):e104870. PubMed ID: 25137071
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exosomal miR-1246 and miR-155 as predictive and prognostic biomarkers for trastuzumab-based therapy resistance in HER2-positive breast cancer.
    Zhang Z; Zhang L; Yu G; Sun Z; Wang T; Tian X; Duan X; Zhang C
    Cancer Chemother Pharmacol; 2020 Dec; 86(6):761-772. PubMed ID: 33068176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of circulating miR-21, -205, and -182 with response of luminal breast cancers to neoadjuvant FAC and AC treatment.
    Chekhun VF; Borikun TV; Bazas VМ; Andriiv AV; Klyusov OМ; Yalovenko TМ; Lukianova NY
    Exp Oncol; 2020 Sep; 42(3):162-166. PubMed ID: 32996748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial.
    Di Cosimo S; Appierto V; Pizzamiglio S; Tiberio P; Iorio MV; Hilbers F; de Azambuja E; de la Peña L; Izquierdo M; Huober J; Baselga J; Piccart M; de Braud FG; Apolone G; Verderio P; Daidone MG
    Clin Cancer Res; 2019 Jul; 25(13):3887-3895. PubMed ID: 30814109
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Candidate circulating microRNAs as potential diagnostic and predictive biomarkers for the monitoring of locally advanced breast cancer patients.
    Ibrahim AM; Said MM; Hilal AM; Medhat AM; Abd Elsalam IM
    Tumour Biol; 2020 Oct; 42(10):1010428320963811. PubMed ID: 33028151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer.
    Wu X; Somlo G; Yu Y; Palomares MR; Li AX; Zhou W; Chow A; Yen Y; Rossi JJ; Gao H; Wang J; Yuan YC; Frankel P; Li S; Ashing-Giwa KT; Sun G; Wang Y; Smith R; Robinson K; Ren X; Wang SE
    J Transl Med; 2012 Mar; 10():42. PubMed ID: 22400902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum Tumor Marker Levels might have Little Significance in Evaluating Neoadjuvant Treatment Response in Locally Advanced Breast Cancer.
    Wang YJ; Huang XY; Mo M; Li JW; Jia XQ; Shao ZM; Shen ZZ; Wu J; Liu GY
    Asian Pac J Cancer Prev; 2015; 16(11):4603-8. PubMed ID: 26107211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial.
    Müller V; Gade S; Steinbach B; Loibl S; von Minckwitz G; Untch M; Schwedler K; Lübbe K; Schem C; Fasching PA; Mau C; Pantel K; Schwarzenbach H
    Breast Cancer Res Treat; 2014 Aug; 147(1):61-8. PubMed ID: 25086636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of miRNA Signature in Breast Cancer to Predict Neoadjuvant Chemotherapy Response.
    Xing AY; Wang B; Li YH; Chen X; Wang YW; Liu HT; Gao P
    Pathol Oncol Res; 2021; 27():1609753. PubMed ID: 34257614
    [No Abstract]   [Full Text] [Related]  

  • 15. The correlation of circulating pro-angiogenic miRNAs' expressions with disease risk, clinicopathological features, and survival profiles in gastric cancer.
    Peng W; Liu YN; Zhu SQ; Li WQ; Guo FC
    Cancer Med; 2018 Aug; 7(8):3773-3791. PubMed ID: 30003708
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
    Robelin P; Tod M; Colomban O; Lachuer J; Ray-Coquard I; Rauglaudre G; Joly F; Chevalier-Place A; Combe P; Lortholary A; Hamizi S; Raban N; Ferron G; Meunier J; Berton-Rigaud D; Alexandre J; Kaminsky MC; Dubot C; Leary A; Malaurie E; You B
    Gynecol Oncol; 2020 Oct; 159(1):256-263. PubMed ID: 32712155
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue and Serum miRNA Profile in Locally Advanced Breast Cancer (LABC) in Response to Neo-Adjuvant Chemotherapy (NAC) Treatment.
    Al-Khanbashi M; Caramuta S; Alajmi AM; Al-Haddabi I; Al-Riyami M; Lui WO; Al-Moundhri MS
    PLoS One; 2016; 11(4):e0152032. PubMed ID: 27064979
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating microRNAs from the miR-106a-363 cluster on chromosome X as novel diagnostic biomarkers for breast cancer.
    Li M; Zhou Y; Xia T; Zhou X; Huang Z; Zhang H; Zhu W; Ding Q; Wang S
    Breast Cancer Res Treat; 2018 Jul; 170(2):257-270. PubMed ID: 29557526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant Chemotherapy in Breast Cancer Patients Induces miR-34a and miR-122 Expression.
    Frères P; Josse C; Bovy N; Boukerroucha M; Struman I; Bours V; Jerusalem G
    J Cell Physiol; 2015 Feb; 230(2):473-81. PubMed ID: 25078559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Age-related microRNAs in older breast cancer patients: biomarker potential and evolution during adjuvant chemotherapy.
    Dalmasso B; Hatse S; Brouwers B; Laenen A; Berben L; Kenis C; Smeets A; Neven P; Schöffski P; Wildiers H
    BMC Cancer; 2018 Oct; 18(1):1014. PubMed ID: 30348127
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.